Gemcitabine

Generic Name: Gemcitabine

Brand Names: Gemzar

Drug Type: Small Molecule

Chemical Formula: C_₉H_₁₁F_₂N_₃O_₄

CAS Number: 95058-81-4

Unique Ingredient Identifier: B76N6SBZ8R

Background: Gemcitabine is a nucleoside analog and a chemotherapeutic agent. It was originally investigated for its antiviral effects, but it is now used as an anticancer therapy for various cancers. Gemcitabine is a cytidine analog with two fluorine atoms replacing the hydroxyl on the ribose. As a prodrug, gemcitabine is transformed into its active metabolites that wor...

Indication: Gemcitabine is a chemotherapeutic agent used as monotherapy or in combination with other anticancer agents.

In combination with carboplatin, it is indicated for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy.
...

Associated Conditions: Advanced Ovarian Cancer, Bladder Transitional Cell Carcinoma Stage IV, Carcinoma of the Head and Neck, Cervical Cancer, Cutaneous T-Cell Lymphoma (CTCL), Hodgkins Disease (HD), Mesothelioma, Metastatic Breast Cancer, Pancreatic Adenocarcinoma Locally Advanced, Small Cell Lung Cancer (SCLC), Stage IIIA Non Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer (NSCLC), Stage 4 Pancreatic adenocarcinoma

Associated Therapies: -

Clinical Trials

Surveillance of the Genetic Signature in Circulating Tumor DNA for Guiding Adjuvant Chemotherapy in Urothelial Carcinoma: A Pilot Randomized Controlled Trial

Phase 2

Recruiting

Conditions: Muscle Invasive Bladder Urothelial Carcinoma
Muscle-Invasive Bladder Carcinoma

Interventions: Drug: gemcitabine
Drug: Cisplatin

First Posted Date: 2024-02-13

Last Posted Date: 2024-02-13

Lead Sponsor: Yung NA

Target Recruit Count: 20

Registration Number: NCT06257017

Locations: 🇭🇰
Queen Mary Hospital, Hong Kong, Hong Kong

Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response

Phase 3

Recruiting

Conditions: Nasopharyngeal Carcinoma

Interventions: Drug: PD-1 blocking antibody
Drug: Gemcitabine
Drug: Cisplatin (80 mg/m2)
Radiation: Reduced-dose Intensity-modulated radiotherapy
Radiation: Conventional-dose Intensity-modulated radiotherapy
Drug: Cisplatin (100 mg/m2)
Drug: Capecitabine

First Posted Date: 2024-02-02

Last Posted Date: 2024-04-26

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 593

Registration Number: NCT06239727

Locations: 🇨🇳
Zhongshan city Peaple's Hospital, Zhongshan, Guangdong, China
🇨🇳
Union Hospital Affiliated with Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei, China
🇨🇳
Xiangya Hospital Central South University, Changsha, Hunan, China

and more 5 locations

A Study of the Treatment of Disitamab Vedotin in Patients With Locally Advanced or Metastatic Pancreatic Cancer

Phase 2

Not yet recruiting

Conditions: Pancreatic Cancer

Interventions: Drug: Disitamab Vedotin
Drug: Gemcitabine

First Posted Date: 2024-01-31

Last Posted Date: 2024-04-17

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 63

Registration Number: NCT06233864

A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma

Phase 3

Recruiting

Conditions: B-Cell Non-Hodgkin Lymphoma (B-NHL)

Interventions: Drug: Odronextamab
Drug: Ifosfamide
Drug: Carboplatin
Drug: Etoposide
Drug: Rituximab
Drug: Dexamethasone
Drug: Cisplatin
Drug: Cytarabine
Drug: Gemcitabine

First Posted Date: 2024-01-30

Last Posted Date: 2024-12-10

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 216

Registration Number: NCT06230224

Locations: 🇨🇳
Chang Gung Memorial Hospital Kaohsiung, Kaohsiung City, Taiwan
🇹🇷
VM Medical Park Mersin Hospital, Mezitli, Mersin, Turkey
🇦🇺
Princess Alexandra Hospital, Woolloongabba, Queensland, Australia

and more 54 locations

Precise Neoadjuvant Chemoresection of Low Grade NMIBC

Phase 2

Not yet recruiting

Conditions: Bladder Cancer
Non-muscle Invasive Bladder Cancer
Low-risk

Interventions: Drug: Epirubicin
Drug: Gemcitabine
Drug: Mitomycin
Drug: Docetaxel

First Posted Date: 2024-01-26

Last Posted Date: 2024-01-26

Lead Sponsor: University of Bern

Target Recruit Count: 28

Registration Number: NCT06227065

Locations: 🇨🇭
Roland Seiler, Biel, Switzerland

AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2

Phase 2

Recruiting

Conditions: Gastric Cancer
Pancreatic Adenocarcinoma
Gastroesophageal Junction Cancer

Interventions: Drug: AZD0901
Drug: 5-Fluorouracil
Drug: Leucovorin
Drug: l-leucovorin
Drug: Irinotecan
Drug: Nanoliposomal Irinotecan
Drug: Gemcitabine

First Posted Date: 2024-01-23

Last Posted Date: 2024-10-04

Lead Sponsor: AstraZeneca

Target Recruit Count: 123

Registration Number: NCT06219941

Locations: 🇬🇧
Research Site, Oxford, United Kingdom

A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)

Phase 3

Recruiting

Conditions: Non-Muscle Invasive Bladder Neoplasms

Interventions: Drug: TAR-200
Drug: Mitomycin C
Drug: Gemcitabine

First Posted Date: 2024-01-18

Last Posted Date: 2024-12-06

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 250

Registration Number: NCT06211764

Locations: 🇺🇸
Low Country Urology Clinics, North Charleston, South Carolina, United States
🇺🇸
Houston Metro Urology, Houston, Texas, United States
🇺🇸
The Urology Group, Cincinnati, Ohio, United States

and more 111 locations